These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 20414023)
1. [Trastuzumab-associated cardiac dysfunction]. Okada Y; Kanbayashi C; Sato N Gan To Kagaku Ryoho; 2010 Apr; 37(4):665-9. PubMed ID: 20414023 [TBL] [Abstract][Full Text] [Related]
2. [Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography]. Hattori K; Nishi Y; Nakamura S; Misao H; Kikuchi M; Sasaki R; Takeda K Rinsho Byori; 2007 Feb; 55(2):120-5. PubMed ID: 17390714 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab in breast cancer: experience from the University of Florence. Livi L; Borghesi S; Meattini I; Saieva C; De Luca Cardillo C; Scotti V; Mangoni M; Galardi A; Cataliotti L; Paiar F; Bianchi S; Biti G J Chemother; 2010 Apr; 22(2):115-8. PubMed ID: 20435571 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P; J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778 [TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555 [TBL] [Abstract][Full Text] [Related]
6. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152 [TBL] [Abstract][Full Text] [Related]
7. [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations]. Tanz R; Mahfoud T; Bazine A; Khmamouch R; Bensouda Y; Ismaili N; Benjaafar N; El Gueddari BK; Ichou M; Errihani H J Gynecol Obstet Biol Reprod (Paris); 2011 Apr; 40(2):144-8. PubMed ID: 21227599 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669 [TBL] [Abstract][Full Text] [Related]
9. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614 [TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer]. Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465 [TBL] [Abstract][Full Text] [Related]
12. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Hare JL; Brown JK; Leano R; Jenkins C; Woodward N; Marwick TH Am Heart J; 2009 Aug; 158(2):294-301. PubMed ID: 19619708 [TBL] [Abstract][Full Text] [Related]
13. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934 [TBL] [Abstract][Full Text] [Related]
14. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis. Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J Oncology; 2013; 85(4):228-34. PubMed ID: 24081024 [TBL] [Abstract][Full Text] [Related]
15. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349 [TBL] [Abstract][Full Text] [Related]
17. [Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: case report and review of recommendations]. Duchnowska R; Szmit S; Szczylik C; Opolski G Kardiol Pol; 2008 Aug; 66(8):895-8. PubMed ID: 18803144 [No Abstract] [Full Text] [Related]
18. The cardiac safety of trastuzumab in the treatment of breast cancer. Chien AJ; Rugo HS Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700 [TBL] [Abstract][Full Text] [Related]
20. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]